Yunnan Baiyao Group Co.,Ltd

Shenzhen Stock Exchange 000538.SZ

Yunnan Baiyao Group Co.,Ltd EBIT for the year ending December 31, 2023: USD 598.34 M

Yunnan Baiyao Group Co.,Ltd EBIT is USD 598.34 M for the year ending December 31, 2023, a 20.82% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Yunnan Baiyao Group Co.,Ltd EBIT for the year ending December 31, 2022 was USD 495.23 M, a -11.62% change year over year.
Yunnan Baiyao Group Co.,Ltd EBIT for the year ending December 31, 2021 was USD 560.32 M, a -47.55% change year over year.
Yunnan Baiyao Group Co.,Ltd EBIT for the year ending December 31, 2020 was USD 1.07 B, a 51.51% change year over year.
Yunnan Baiyao Group Co.,Ltd EBIT for the year ending December 31, 2019 was USD 705.08 M, a 20.46% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Shenzhen Stock Exchange: 000538.SZ

Yunnan Baiyao Group Co.,Ltd

CEO	Mr. Ming Dong
IPO Date	Dec. 15, 1993
Location	China
Headquarters	No. 3686, Yunnan Baiyao Street
Employees	8,834
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Yunnan Baiyao Group Co.,Ltd engages in the pharmaceutical business in China and internationally. It provides health products, drugs, medical instruments, Chinese medicine resources, and tea. The company offers its products under the Yunnan Baiyao, Yunfeng, Tong Qiaoqiao, Yunjian, Life, Jinkoujian, Langjian, Yangyuanqing, Caizhiji, Baiyao Health, Leopard Seven, Qiancaotang, Qiancao Meizi, and Tianzihong brand names. Yunnan Baiyao Group Co., Ltd. was founded in 1902 and is based in Kunming, China.

Key trends

Past 5 years